MacroGenics, Inc. (MGNX)

Market Cap	1.01B
Revenue (ttm)	58.75M
Net Income (ttm)	-9.06M
Shares Out	62.03M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	646,310
Open	15.65
Previous Close	15.41
Day's Range	15.60 - 16.59
52-Week Range	4.29 - 21.88
Beta	2.11
Analysts	Strong Buy
Price Target	21.50 (+32.47%)
Earnings Date	May 7, 2024

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibod...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 339
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX

Financial Performance

In 2023, MacroGenics's revenue was $58.75 million, a decrease of -61.33% compared to the previous year's $151.94 million. Losses were -$9.06 million, -92.44% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for MGNX stock is "Strong Buy." The 12-month stock price forecast is $21.5, which is an increase of 32.47% from the latest price.

Price Target

$21.5

(32.47% upside)

Analyst Consensus: Strong Buy